 


About :: Cerecor, Inc. (CERC)















 





















A Leading Neuroscience Company
Developing innovative therapies for multiple indications with high unmet needs












        	About        



About





Making a Difference in the Lives of Patients with Neurological and Psychiatric Disorders
Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. We systematically identify platforms and product candidates for which human proof of concept exists in the intended indication, for either the target or the compound, and for which biomarkers are available to measure therapeutic response. View our Pipeline









Extensive Product Development and Commercialization Experience
Members of our management team have extensive pharmaceutical product development and commercialization experience and have played key roles in the development or commercialization of Prozac®, Zyprexa®, Cymbalta®, Nuplazid™ and Abilify®, each of which is a neuroscience product that has generated more than $1 billion of annual revenues, or has the potential to do so. Collectively, our officers and directors have contributed to the submission of numerous Investigational New Drug Applications (IND) and nine New Drug Applications (NDA) to the FDA. View Our Stock Info










Management Team




Board of Directors








 


 







Company Information :: Cerecor, Inc. (CERC)

















 





















Company Information












        	Investors        











Company Information
Company Profile
Cerecor is a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders. Cerecor is currently pursuing the development of two clinical Phase 2-stage product candidates, CERC-301 and CERC-501; as well as two earlier stage programs.
View Profile
View Management Team






Latest Presentation

Investor Presentation
View This Presentation






Contact Information




Investor Relations ir@cerecor.com 



Company Contact
                    Cerecor, Inc.                    400 East Pratt Street                    Baltimore, MD 21202



 







 


 


Cerecor, Inc. (CERC)















 




















Continue





Improving Lives, Making a Difference
At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.
How We’re Making a Difference










Improving Lives, Making a Difference
At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.
How We’re Making a Difference










Improving Lives, Making a Difference
At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.
How We’re Making a Difference










Improving Lives, Making a Difference
At Cerecor, we are committed to developing drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders.
How We’re Making a Difference







Home





Welcome to Cerecor
Cerecor is a Baltimore-based biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases. 








About CNS
Learn more about the CNS disorders we’re targeting, as well as contact information for help hotlines. Learn More About CNS Disorders









Backed by More Than 100 Collective Years of Experience
The members of our team have extensive pharmaceutical product development and commercialization experience and have played key roles in the development or commercialization of Prozac®, Zyprexa®, Cymbalta®, Nuplazid™ and Abilify®. View Management Team












Uli Hacksell, Ph.D.
Chief Executive Officer, President, and Chairman of the Board of Directors
View Full Profile








Ronald Marcus, M.D.
Chief Medical Officer and Head, Regulatory Affairs
View Full Profile








Mariam E. Morris, CPA
Chief Financial Officer
View Full Profile








John Kaiser
Chief Business Officer
View Full Profile














Uli Hacksell, Ph.D.
Chief Executive Officer, President, and Chairman of the Board of Directors



Dr. Hacksell was appointed CEO & President of Cerecor Inc. in January of 2016. Dr. Hacksell also serves as Chairman of the Board of Directors, a position he has held since May of 2015. Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery. Prior to ACADIA, Dr. Hacksell held various senior executive positions at Astra AB, or Astra, a pharmaceutical company, including Vice President of Drug Discovery and Technology, President of Astra Draco, one of Astra’s largest research and development subsidiaries, and Vice President of CNS Preclinical R&D at Astra Arcus, another Astra subsidiary. Earlier in his career, Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University in Sweden and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. Dr. Hacksell is currently Chairman of the Board of Directors of Glionova Therapeutics and is also a member of the Board of Directors of InDex Pharmaceuticals and Uppsala University. He received a Master of Pharmacy and a Ph.D. in Medicinal Chemistry from Uppsala University. 









Ronald Marcus, M.D.
Chief Medical Officer and Head, Regulatory Affairs



Dr. Marcus has served as our Chief Medical Officer and Head of Regulatory Affairs since May 2015. He has more than 20 years of experience in the development of neuroscience drugs at both Spinifex Pharmaceuticals, or Spinifex, and Bristol-Myers Squibb. Dr. Marcus was most recently the Chief Medical Officer at Spinifex, where he was responsible for driving clinical development and regulatory strategy of its lead compound for neuropathic pain. Prior to that, Dr. Marcus held various positions at Bristol-Myers Squibb including Group Director of Neuroscience Strategic Unit and Executive Director of Neuroscience Global Clinical Research. In this role, he was Early Development Team Leader for neuropathic pain, schizophrenia and migraine compounds and Life-Cycle Management Team Leader for Abilify®, which included the development of Abilify® for the adjunctive treatment of depression. He has extensive experience in early drug development and possesses both breadth and depth in all of the key functional areas of exploratory and late development, disease biology and regulatory affairs. Dr. Marcus has been recognized within the biopharmaceutical industry for his excellence in overall drug development, innovative strategic leadership and executional excellence while spearheading an industry-leading life cycle management program for Abilify®. In addition to the approval of over 20 New Drug Applications (NDA) and supplemental NDAs globally for Abilify®, Dr. Marcus also led the successful development of Serzone®, an antidepressant. Further, Dr. Marcus has authored more than 80 peer-reviewed publications. Dr. Marcus received his B.A. in Psychology from the University of Virginia. He earned his M.D. from SUNY Buffalo and completed his psychiatry residency and the National Institute of Mental Health research fellowship at Cornell University, New York Hospital-Westchester Division. 









Mariam E. Morris, CPA
Chief Financial Officer



Mariam E. Morris joined Cerecor Pharmaceuticals as Chief Financial Officer in 2015, leading Cerecor through its initial public offering and currently serves as the Company’s Secretary and Treasurer. Mariam is a seasoned financial executive and comes to Cerecor with over 20 years of experience and having owned her own consulting firm for the past six years. While consulting, Mariam worked with several business as out-sourced CFO and CBO roles. Prior to owning her own firm, Mariam was the Chief Financial Officer of Sucampo Pharmaceuticals. (NASDAQ: SCMP). Her years of experience include strategic planning, investor relations, human resources, internal controls for public and private companies, SOX compliance, and oversite of human resources and information technology. Mariam has significant SEC reporting, tax, acquisition, technical accounting, budgeting, treasury, operations and project management experience. She has a Masters in Taxation from Old Dominion University, a B.A. in Accounting from Texas Tech University, and is a member of the AICPA and TSCPA. 









John Kaiser
Chief Business Officer



Mr. Kaiser serves as Cerecor's Chief Business Officer with responsibilities for corporate strategy, strategic marketing and business development and led the company to acquire both CERC-301 and CERC-501 in 2013 and 2015 respectively. Prior to joining Cerecor, Mr. Kaiser founded Denysias Bioscience, LLC, a biopharmaceutical company focused on developing new therapies for neuropsychiatric disorders, where he served as Chief Executive Officer. At the same time, Mr. Kaiser also served as President of Kaiser & Associates Consulting, a boutique consulting firm providing strategic corporate and commercial expertise to the biopharmaceutical industry. From 2008-2009, Mr. Kaiser served as Vice President of Commercial and Business Development at ACADIA Pharmaceuticals Inc. Before ACADIA, Mr. Kaiser held numerous positions of increasing responsibilities in sales, marketing and general management at Eli Lilly and Company in a career of more than 25 years. At Lilly, Mr. Kaiser led the global commercialization efforts of Prozac®, the global strategic marketing efforts for Cymbalta®, and helped drive the commercial success of Zyprexa® internationally. Mr. Kaiser also led the strategic marketing efforts for the company's CNS development portfolio and co-led the development and execution of the company's CNS strategy. Mr. Kaiser is a member of Cerecor's Senior Management Team and currently serves on the Board of Directors of NHTherapeutics. Mr. Kaiser received his B.S. in pharmaceutical sciences from the James L. Winkle College of Pharmacy at the University of Cincinnati. 







Recent News



May 30, 2017 • 12:00 AM EDT
Cerecor to present at the American Society for Clinical Psychopharmacology Conference


May 15, 2017 • 12:00 AM EDT
Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors



View All News





Investor Relations


Cerecor, Inc. 


NASDAQ: CERC
Symbol



Price


 
Change





Volume



Day Range



52 Week Range





Latest Investor Presentation


View Latest 10-K


View Investor Relations










 





Cerecor Inc. - Product Pipeline Review - 2014































| Compare 
About Us | 
Contact Us






Home
Research Category
Publisher List
Custom Research
Cart
Compare



Research Category
User Guide
Policies
Contact Us
About us
Site Map











Home > Market Research Report  > Pharmaceutical > Pharmaceutical Companies









Market Research Report
Cerecor Inc. - Product Pipeline Review - 2014



Published by
Global Markets Direct
Product code
285616


Published
December 10, 2014
Content info
25 Pages 


Price








USD 1500

PDF by E-mail (Single user license)





USD 3000

PDF by E-mail (Site license)





USD 4500

PDF by E-mail (Global license)
























Cerecor Inc. - Product Pipeline Review - 2014



Published: December 10, 2014
Content info: 25 Pages














Description


Summary
Global Markets Direct's, 'Cerecor Inc. - Product Pipeline Review - 2014', provides an overview of the Cerecor Inc.'s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Cerecor Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope

 The report provides brief overview of Cerecor Inc. including business description, key information and facts, and its locations and subsidiaries
 The report reviews current pipeline of Cerecor Inc.'s human therapeutic division and enlists all their major and minor projects
 The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
 Special feature on out-licensed and partnered product portfolio
 The report summarizes all the dormant and discontinued pipeline projects
 Latest company statement
 Latest news and deals relating to the Cerecor Inc.'s pipeline products

Reasons to buy

 Evaluate Cerecor Inc.'s strategic position with total access to detailed information on its product pipeline
 Assess the growth potential of Cerecor Inc. in its therapy areas of focus
 Identify new drug targets and therapeutic classes in the Cerecor Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 Develop strategic initiatives by understanding the focus areas of Cerecor Inc. and exploit collaboration and partnership opportunities
 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cerecor Inc.
 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Explore the dormant and discontinued projects of Cerecor Inc. and identify potential opportunities in those areas
 Avoid Intellectual Property Rights related issues




Table of Contents
Product Code: GMDHC06624CDBTable of Contents

Table of Contents 

List of Tables 
List of Figures 

Cerecor Inc. Snapshot 

Cerecor Inc. Overview 
Key Information 
Key Facts 

Cerecor Inc. - Research and Development Overview 

Key Therapeutic Areas 

Cerecor Inc. - Pipeline Review 

Pipeline Products by Stage of Development 
Pipeline Products - Monotherapy 

Cerecor Inc. - Pipeline Products Glance 

Cerecor Inc. - Clinical Stage Pipeline Products 

Phase II Products/Combination Treatment Modalities 

Cerecor Inc. - Early Stage Pipeline Products 

Preclinical Products/Combination Treatment Modalities 


Cerecor Inc. - Drug Profiles 

CERC-301 

Product Description 
Mechanism of Action 
R&D Progress

memantine hydrochloride 

Product Description 
Mechanism of Action 
R&D Progress

2-MPPA 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit COMT for Cognitive Disorders 

Product Description 
Mechanism of Action 
R&D Progress


Cerecor Inc. - Pipeline Analysis 

Cerecor Inc. - Pipeline Products by Target 
Cerecor Inc. - Pipeline Products by Route of Administration 
Cerecor Inc. - Pipeline Products by Molecule Type 
Cerecor Inc. - Pipeline Products by Mechanism of Action 

Cerecor Inc. - Recent Pipeline Updates 
Cerecor Inc. - Dormant Projects 
Cerecor Inc. - Discontinued Pipeline Products 

Discontinued Pipeline Product Profiles 

CERC-301 


Cerecor Inc. - Locations And Subsidiaries 

Head Office 

Appendix 

Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 


List of Tables

Cerecor Inc., Key Information 
Cerecor Inc., Key Facts 
Cerecor Inc. - Pipeline by Indication, 2014 
Cerecor Inc. - Pipeline by Stage of Development, 2014 
Cerecor Inc. - Monotherapy Products in Pipeline, 2014 
Cerecor Inc. - Phase II, 2014 
Cerecor Inc. - Preclinical, 2014 
Cerecor Inc. - Pipeline by Target, 2014 
Cerecor Inc. - Pipeline by Route of Administration, 2014 
Cerecor Inc. - Pipeline by Molecule Type, 2014 
Cerecor Inc. - Pipeline Products by Mechanism of Action, 2014 
Cerecor Inc. - Recent Pipeline Updates, 2014 
Cerecor Inc. - Dormant Developmental Projects,2014 
Cerecor Inc. - Discontinued Pipeline Products, 2014 

List of Figures

Cerecor Inc. - Pipeline by Top 10 Indication, 2014 
Cerecor Inc. - Pipeline by Stage of Development, 2014 
Cerecor Inc. - Monotherapy Products in Pipeline, 2014 
Cerecor Inc. - Pipeline by Top 10 Target, 2014 
Cerecor Inc. - Pipeline by Top 10 Route of Administration, 2014 
Cerecor Inc. - Pipeline by Top 10 Molecule Type, 2014 
Cerecor Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 








Phone


Int'l: +1-860-674-8796
TollFree(US): +1-866-353-3335
Europe: +32-2-535-7543
Asia: +65-6223-2436


New for 2017 !

GII now purchases any market research reports from any publishers for you.  
			With noextra cost.
Contact us for more details.

FAQ


Delivery Time
User License
Payment Options
Compare Multiple Reports
















About
Contact
User Guide
Policies
Site Map



© Copyright 1997-2017, Global Information, Inc. All rights reserved.








    CERC Key Statistics - Cerecor Inc. Financial Ratios - MarketWatch




































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Cerecor Inc.

                  NASDAQ: CERC
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Cerecor Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 27, 2017, 3:59 p.m.


CERC

/quotes/zigman/53389169/composite


$
0.75




Change

-0.07
-8.54%

Volume
Volume 612,448
Quotes are delayed by 20 min








/quotes/zigman/53389169/composite
Previous close

$
			0.82
		


$
				0.75
			
Change

-0.07
-8.54%





Day low
Day high
$0.73
$0.85










52 week low
52 week high

            $0.34
        

            $5.60
        

















			Company Description 


			Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was foun...
		


                Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
            




Valuation

P/E Current
-0.39


P/E Ratio (with extraordinary items)
-0.56


Price to Sales Ratio
6.74


Price to Book Ratio
40.13


Enterprise Value to EBITDA
-0.48


Enterprise Value to Sales
5.05


Total Debt to Enterprise Value
0.47

Efficiency

Revenue/Employee
76,866.00


Income Per Employee
-1,098,107.00


Receivables Turnover
17.41


Total Asset Turnover
0.08

Liquidity

Current Ratio
1.31


Quick Ratio
1.31


Cash Ratio
1.19



Profitability

Operating Margin
-1,394.64


Pretax Margin
-1,428.60


Net Margin
-1,428.60


Return on Assets
-120.11


Return on Equity
-247.87


Return on Total Capital
-155.35


Return on Invested Capital
-210.58

Capital Structure

Total Debt to Total Equity
1,137.03


Total Debt to Total Capital
91.92


Total Debt to Total Assets
40.80





      Officers and Executives
    



Name
Age
Officer Since
Title





Dr. Uli  Hacksell 
64
2015
Chairman, President & Chief Executive Officer



Ms. Mariam E. Morris 
48
2015
CFO & Principal Accounting Officer



Mr. John Joseph Kaiser 
60
2012
Chief Business Officer



Mr. Peter S. Greenleaf 
47
2017
Director



Mr. Steven Joseph Boyd 
-
2017
Director





Insider Actions


 – Purchase

 – Sale
1
 – Number of Transactions











{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}


Date
Name
Shares
Transaction
Value





07/06/2017

Armistice Capital LLC                            
Director

11,940,000


 
Derivative/Non-derivative trans. at $0.35 per share.


4,179,000


07/06/2017

Armistice Capital LLC                            
Director

11,940,000


 
Derivative/Non-derivative trans. at $0.35 per share.


4,179,000


07/06/2017

Armistice Capital LLC                            
Director

11,940,000


 
Derivative/Non-derivative trans. at $0.35 per share.


4,179,000


05/19/2017

Armistice Capital LLC                            
Director

24,224


 
Acquisition at $0.63 per share.


15,261


05/19/2017

Armistice Capital LLC                            
Director

24,224


 
Acquisition at $0.63 per share.


15,261


05/19/2017

Armistice Capital LLC                            
Director

24,224


 
Acquisition at $0.63 per share.


15,261


05/10/2017

Armistice Capital LLC                            
Director

27,819


 
Acquisition at $0.79 per share.


21,977


05/10/2017

Armistice Capital LLC                            
Director

27,819


 
Acquisition at $0.79 per share.


21,977


05/10/2017

Armistice Capital LLC                            
Director

27,819


 
Acquisition at $0.79 per share.


21,977


05/09/2017

Armistice Capital LLC                            
Director

36,059


 
Acquisition at $0.66 per share.


23,798


05/09/2017

Armistice Capital LLC                            
Director

36,059


 
Acquisition at $0.66 per share.


23,798


05/09/2017

Armistice Capital LLC                            
Director

36,059


 
Acquisition at $0.66 per share.


23,798


05/05/2017

Armistice Capital LLC                            
Director

15,798


 
Acquisition at $0.63 per share.


9,952


05/04/2017

Armistice Capital LLC                            
Director

28,413


 
Acquisition at $0.63 per share.


17,900


05/04/2017

Armistice Capital LLC                            
Director

28,413


 
Acquisition at $0.63 per share.


17,900


05/04/2017

Armistice Capital LLC                            
Director

28,413


 
Acquisition at $0.63 per share.


17,900


05/03/2017

Armistice Capital LLC                            
Director

68,359


 
Acquisition at $0.55 per share.


37,597


05/03/2017

Armistice Capital LLC                            
Director

68,359


 
Acquisition at $0.55 per share.


37,597


05/03/2017

Armistice Capital LLC                            
Director

68,359


 
Acquisition at $0.55 per share.


37,597


05/02/2017

Armistice Capital LLC                            
Director

146,095


 
Acquisition at $0.53 per share.


77,430


05/02/2017

Armistice Capital LLC                            
Director

146,095


 
Acquisition at $0.53 per share.


77,430


05/02/2017

Armistice Capital LLC                            
Director

146,095


 
Acquisition at $0.53 per share.


77,430


05/01/2017

Armistice Capital LLC                            
Director

105,620


 
Acquisition at $0.5 per share.


52,810


05/01/2017

Armistice Capital LLC                            
Director

105,620


 
Acquisition at $0.5 per share.


52,810


05/01/2017

Armistice Capital LLC                            
Director

105,620


 
Acquisition at $0.5 per share.


52,810


04/28/2017

Armistice Capital LLC                            
Director

450,000


 
Acquisition at $0.44 per share.


198,000


04/28/2017

Armistice Capital LLC                            
Director

450,000


 
Acquisition at $0.44 per share.


198,000


04/28/2017

Armistice Capital LLC                            
Director

450,000


 
Acquisition at $0.44 per share.


198,000








/news/latest/company/us/cerc

      MarketWatch News on CERC
    




 Ciao, euro! Global markets gird for the next wave of global populism
12:51 p.m. Dec. 5, 2016
 - Shawn Langlois




 Cerecor Inc. shares drop 37% after midstage trial failure
9:14 a.m. Dec. 5, 2016
 - Emma Court




 Cerecor's stock extends slide, plunges 37% premarket after failed drug trial
9:09 a.m. Dec. 5, 2016
 - Tomi Kilgore




 Cerecor says mid-stage trial of treatment for nicotine withdrawal missed its target
9:05 a.m. Dec. 5, 2016
 - Ciara Linnane




 Cerecor's stock tumbles 14% premarket after drug trial fails to meet primary endpoint
9:05 a.m. Dec. 5, 2016
 - Tomi Kilgore




 Cerecor's stock on track to open at all-time low
9:06 a.m. Dec. 5, 2016
 - Tomi Kilgore









/news/nonmarketwatch/company/us/cerc

      Other News on CERC
    





Air Products & Chemicals, Inc. (APD) and United Security Bancshares (USBO) Lead 14 Investor Filings

11:30 a.m. May 18, 2017
 - InvestorPlace.com





InsiderInsights.com Daily Round Up 5/9/17: REV, OPK, RDUS

7:52 a.m. May 10, 2017
 - Seeking Alpha





CenturyLink Inc (CTL), Tripadvisor Inc (TRIP) Lead 17 Notable Investor Filings

1:19 p.m. May 9, 2017
 - InvestorPlace.com




 10-Q: CERECOR INC.
11:12 a.m. May 9, 2017
 - Edgar Online -  (EDG = 10Q, 10K)





Cerecor closes private placement of common stock at $0.35 a share; shares down 21%

9:46 a.m. April 28, 2017
 - Seeking Alpha




 10-K: CERECOR INC.
4:33 p.m. March 14, 2017
 - Edgar Online -  (EDG = 10Q, 10K)





11 Pharmaceuticals Stocks to Sell Now

10:30 a.m. Dec. 9, 2016
 - InvestorPlace.com





Cerecor's CERC-501 flunks mid-stage study; shares off 31%

11:47 a.m. Dec. 5, 2016
 - Seeking Alpha





Biggest Movers in Manufacturing Stocks Now – CSBR NVET CRR HES

11:45 a.m. Nov. 30, 2016
 - InvestorPlace.com





Cerecor's lead product candidate flunks mid-stage study in MDD; shares plummet 47% after hours

5:37 p.m. Nov. 29, 2016
 - Seeking Alpha





Hottest Manufacturing Stocks Now – ENTA KTEC MOV MT

11:15 a.m. Nov. 22, 2016
 - InvestorPlace.com





Cerecor's Trial Of CERC-301 In Depression Offers Investors Potential Upside

5:35 p.m. Nov. 18, 2016
 - Seeking Alpha




 10-Q: CERECOR INC.
4:16 p.m. Nov. 8, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





Alkermes buying ripples out to Cerecor; shares up 17%

11:19 a.m. Oct. 21, 2016
 - Seeking Alpha





Hottest Manufacturing Stocks Now – ALKS CERC TVIA PTX

11:00 a.m. Oct. 21, 2016
 - InvestorPlace.com





Hottest Manufacturing Stocks Now – MBRX IPCI TANH MTL

10:30 a.m. Oct. 19, 2016
 - InvestorPlace.com





Biggest Movers in Manufacturing Stocks Now – CERC KMG ASMB SKY

4:15 p.m. Oct. 14, 2016
 - InvestorPlace.com





Biggest Movers in Manufacturing Stocks Now – ABEO CRIS MDGL EDGE

4:15 p.m. Oct. 5, 2016
 - InvestorPlace.com





Hottest Manufacturing Stocks Now – PZRX COLL IDRA LPCN

4:15 p.m. Sept. 30, 2016
 - InvestorPlace.com





Cerecor nabs rights to epilepsy candidate from Eli Lilly

12:03 p.m. Sept. 26, 2016
 - Seeking Alpha


Loading more headlines...












At a Glance

Cerecor, Inc.
400 East Pratt Street
Suite 606

Baltimore, Maryland 21202




Phone
1 4105228707


Industry
Pharmaceuticals


Sector
Health Care/Life Sciences


Fiscal Year-end
12/2017


View SEC Filings




Revenue
$1.15M


Net Income
$-16.47M


Employees

        15.00


Annual Report for CERC











/news/pressrelease/company/us/cerc

      Press Releases on CERC
    




 Cerecor to present at the American Society for Clinical Psychopharmacology Conference
8:31 a.m. May 30, 2017
 - Marketwired




 Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
8:31 a.m. May 15, 2017
 - Marketwired




 Cerecor Inc. Reports First Quarter 2017 Financial Results
8:31 a.m. May 9, 2017
 - Marketwired




 Cerecor Reports Encouraging Topline Data from a NIH Sponsored Proof-of-Concept Trial of CERC-501 in Treatment-Resistant Depression
8:30 a.m. May 1, 2017
 - Marketwired




 Cerecor Inc. Closes $5.0 Million Private Placement
8:30 a.m. April 28, 2017
 - Marketwired




 Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
9:37 a.m. March 14, 2017
 - Marketwired




 Cerecor Engages SunTrust Robinson Humphrey to Assist with Review of Strategic Alternatives
10:33 a.m. Feb. 7, 2017
 - Marketwired




 Cerecor Announces At-the-Market Equity Offering Program
5:20 p.m. Jan. 27, 2017
 - Marketwired




 Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal
9:11 a.m. Dec. 5, 2016
 - Marketwired




 Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
5:01 p.m. Nov. 29, 2016
 - Marketwired




 Cerecor Inc. Reports Third Quarter 2016 Financial Results
10:16 a.m. Nov. 8, 2016
 - Marketwired




 Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine
3:36 p.m. Nov. 7, 2016
 - Marketwired




 Cerecor to Present at the 15th Annual BIO 
      Investor Forum in San Francisco on October 18th, 2016
9:12 a.m. Oct. 10, 2016
 - BusinessWire - BZX




 Cerecor Announces Acquisition of TARP-8-AMPA Receptor Antagonist 
      (CERC-611) from Lilly
9:10 a.m. Sept. 26, 2016
 - BusinessWire - BZX




 Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial 
      with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive 
      Disorder
9:10 a.m. Sept. 21, 2016
 - BusinessWire - BZX




 Cerecor Enters Into a $15 Million Common Stock Purchase Agreement 
      with Aspire Capital Fund, LLC
9:10 a.m. Sept. 12, 2016
 - BusinessWire - BZX




 Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial 
      with CERC-501 for Smoking Cessation
9:10 a.m. Sept. 6, 2016
 - BusinessWire - BZX




 Cerecor to Present at 23rd Annual NewsMakers 
      in the Biotech Industry Conference in New York City, September 9, 2016
9:10 a.m. Sept. 1, 2016
 - BusinessWire - BZX




 Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical 
      Trial in Smokers
9:10 a.m. Aug. 29, 2016
 - BusinessWire - BZX




 Cerecor to Present at the 18th Annual Rodman 
      & Renshaw Global Investment Conference in New York City September 11-13th, 
      2016
9:10 a.m. Aug. 22, 2016
 - BusinessWire - BZX


Loading more headlines...









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




11:20 PM EDT
July 27, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:11pScaramucci says Trump’s love of pizza shows he’s not an elitist — 5 ways rich people act humble
11:11pWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
11:10pHere are 10 co-workers you should avoid like the plague in meetings
11:04pOne depressing reason millions of people are locked out of the American Dream
11:04pA provocative new analysis suggests you don’t have to take all your antibiotics after all
9:01pIntel earnings have message for AMD and Nvidia: ‘Bring it on’
8:32pAmazon’s free-spending ways hit earnings, but don’t expect a shift to thrift
8:14pRedfin prices IPO higher than expected for $1.2 billion valuation
8:06pSpaceX valuation jumps to $21 billion on new financing round
7:15pHoward Marks says bitcoin isn’t real—and we can all blame millennials for its rise
7:14pHeadline: Sen. Graham: The 'Skinny' Bill Is a Disaster
6:55pSenate passes Russia sanctions bill on 98-2 vote
6:47pScaramucci provides a shocking Bannon comparison that defies anatomy
6:39pEthereum struggles to rise as regulatory scrutiny weighs on digital currency
6:04pThis fund strategist says there’s at least one way companies can survive Amazon’s onslaught
6:03pThis basic balanced index fund is beating the hedge fund averages
5:48pTesla earnings: Will Model 3 live up to the hype?
5:48pWhat a constant stream of oil company spending cuts means for crude prices
5:43pAll the companies in Jeff Bezos’s empire, in one (large) chart
5:33pBitcoin investors: things may get very ugly soon, if this chart overlay is right
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,796.55

+85.54
+0.39%





nasdaq

/quotes/zigman/12633936/realtime
6,382.19

-40.56
-0.63%





s&p 500

/quotes/zigman/3870025/realtime
2,475.42

-2.41
-0.10%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15























































 







Investor Relations :: Cerecor, Inc. (CERC)

















 





















Investor Relations












        	Investors        



Investor Relations



Latest News View All News
May 30, 2017 • 12:00 AM EDT
Cerecor to present at the American Society for Clinical Psychopharmacology Conference


Stock Information  View Detailed Stock Information






NASDAQ: CERC
Cerecor, Inc.





Price






 
Change





Volume





Day Range





52 Week Range













Company Overview
Cerecor is a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders. Cerecor is currently pursuing the development of two clinical Phase 2-stage product candidates, CERC-301 and CERC-501; as well as two earlier stage programs. 




View Latest Presentation











SEC Filings




Corporate Governance








 









Cerecor Inc. - Product Pipeline Review - 2014























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
Cerecor Inc. - Product Pipeline Review - 2014









 


  Cerecor Inc. - Product Pipeline Review - 2014


WGR12270
10 
                  December, 2014 
Global
25 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





Cerecor Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Cerecor Inc. - Product Pipeline Review - 2014’, provides an overview of the Cerecor Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Cerecor Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of Cerecor Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Cerecor Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the Cerecor Inc.’s pipeline productsReasons to buy- Evaluate Cerecor Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Cerecor Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Cerecor Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Cerecor Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cerecor Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Cerecor Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3Cerecor Inc. Snapshot 4Cerecor Inc. Overview 4Key Information 4Key Facts 4Cerecor Inc. - Research and Development Overview 5Key Therapeutic Areas 5Cerecor Inc. - Pipeline Review 7Pipeline Products by Stage of Development 7Pipeline Products - Monotherapy 8Cerecor Inc. - Pipeline Products Glance 9Cerecor Inc. - Clinical Stage Pipeline Products 9Phase II Products/Combination Treatment Modalities 9Cerecor Inc. - Early Stage Pipeline Products 10Preclinical Products/Combination Treatment Modalities 10Cerecor Inc. - Drug Profiles 11CERC-301 11Product Description 11Mechanism of Action 11R&D Progress 11memantine hydrochloride 12Product Description 12Mechanism of Action 12R&D Progress 122-MPPA 13Product Description 13Mechanism of Action 13R&D Progress 13Small Molecules to Inhibit COMT for Cognitive Disorders 14Product Description 14Mechanism of Action 14R&D Progress 14Cerecor Inc. - Pipeline Analysis 15Cerecor Inc. - Pipeline Products by Target 15Cerecor Inc. - Pipeline Products by Route of Administration 16Cerecor Inc. - Pipeline Products by Molecule Type 17Cerecor Inc. - Pipeline Products by Mechanism of Action 18Cerecor Inc. - Recent Pipeline Updates 19Cerecor Inc. - Dormant Projects 21Cerecor Inc. - Discontinued Pipeline Products 22Discontinued Pipeline Product Profiles 22CERC-301 22Cerecor Inc. - Locations And Subsidiaries 23Head Office 23Appendix 24Methodology 24Coverage 24Secondary Research 24Primary Research 24Expert Panel Validation 24Contact Us 25Disclaimer 25List of TablesCerecor Inc., Key Information 4Cerecor Inc., Key Facts 4Cerecor Inc. - Pipeline by Indication, 2014 6Cerecor Inc. - Pipeline by Stage of Development, 2014 7Cerecor Inc. - Monotherapy Products in Pipeline, 2014 8Cerecor Inc. - Phase II, 2014 9Cerecor Inc. - Preclinical, 2014 10Cerecor Inc. - Pipeline by Target, 2014 15Cerecor Inc. - Pipeline by Route of Administration, 2014 16Cerecor Inc. - Pipeline by Molecule Type, 2014 17Cerecor Inc. - Pipeline Products by Mechanism of Action, 2014 18Cerecor Inc. - Recent Pipeline Updates, 2014 19Cerecor Inc. - Dormant Developmental Projects,2014 21Cerecor Inc. - Discontinued Pipeline Products, 2014 22List of FiguresCerecor Inc. - Pipeline by Top 10 Indication, 2014 6Cerecor Inc. - Pipeline by Stage of Development, 2014 7Cerecor Inc. - Monotherapy Products in Pipeline, 2014 8Cerecor Inc. - Pipeline by Top 10 Target, 2014 15Cerecor Inc. - Pipeline by Top 10 Route of Administration, 2014 16Cerecor Inc. - Pipeline by Top 10 Molecule Type, 2014 17Cerecor Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 18







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,146.60
   

 
  Site PDF 
  
 
  2,293.20
  

 
  Enterprise PDF 
  
 
  3,439.80
  





  1-user PDF
  
 
    1,283.55
   

 
  Site PDF 
  
 
  2,567.10
  

 
  Enterprise PDF 
  
 
  3,850.65
  





  1-user PDF
  
 
    166,629.00
   

 
  Site PDF 
  
 
  333,258.00
  

 
  Enterprise PDF 
  
 
  499,887.00
  





  1-user PDF
  
 
    96,307.50
   

 
  Site PDF 
  
 
  192,615.00
  

 
  Enterprise PDF 
  
 
  288,922.50
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 



































Cerecor Inc. - Product Pipeline Review - 2014



























Sales and support:
        +44 20 8123 2220 (UK)
        +1 732 587 5005 (US)
info@marketpublishers.com





Business & Finance

Retail






Retail


Consumer Goods


Food & Beverage







Industry

Chemicals

IT & Technology

Life Sciences






Medical Devices
Anesthesia & Respiratory
Cardiovascular Devices
Dental
Diabetes Care
Diagnostic Equipment
Drug Delivery
Endoscopy
Ear, Nose & Throat (ENT)
Healthcare Equipment/Supplies Company Reports
Implants
Neurology
Orthopedic
Ophthalmic
Surgical Equipment
Wound Closure
Other Medical Devices


Biotechnology
Biomarkers
Biomaterials
Biosimilars
Stem Cell

Diagnostics & Diseases
In Vitro Diagnostics
Incontinence
Cancer
Cardiovascular
Diabetes
Hepatitis


Healthcare
Healthcare Services Company Reports
Ear Care
Eye Care
Hospital
Medicated Skin Care
Therapy
Wound Care


Pharmaceuticals
Clinical Trial
Drug Stores
Drugs
Pharmaceuticals Company Reports
Vaccines

Medical Products
Veterinary






Services



About
Faq
 My Cart


 











Market Reports
Press-Releases
Events
About Us
Terms & Conditions
Customer FAQ




Market Research Reports

Life Sciences

Pharmaceuticals





Cerecor Inc. - Product Pipeline Review - 2014





Date:
December 10, 2014



Pages:
25


Price:




US$ 1,500.00




License             [?]:


Single-User License - US$ 1,500.00
Site License - US$ 3,000.00
 Enterprisewide License - US$ 4,500.00




Publisher:
Global Markets Direct


Report type:
Company Report


Delivery:

E-mail Delivery (PDF)


ID:
C73FD2931BBEN



        Leaflet:
    

Download PDF Leaflet






















Abstracts
Contents
List of Tables
List of Figures





Cerecor Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Cerecor Inc. - Product Pipeline Review - 2014’, provides an overview of the Cerecor Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Cerecor Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of Cerecor Inc. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of Cerecor Inc.’s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones Special feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statement Latest news and deals relating to the Cerecor Inc.’s pipeline productsReasons to buyEvaluate Cerecor Inc.’s strategic position with total access to detailed information on its product pipelineAssess the growth potential of Cerecor Inc. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the Cerecor Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of Cerecor Inc. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of Cerecor Inc.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of Cerecor Inc. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues



    Cerecor Inc. SnapshotCerecor Inc. OverviewKey InformationKey FactsCerecor Inc. - Research and Development OverviewKey Therapeutic AreasCerecor Inc. - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyCerecor Inc. - Pipeline Products GlanceCerecor Inc. - Clinical Stage Pipeline ProductsPhase II Products/Combination Treatment ModalitiesCerecor Inc. - Early Stage Pipeline ProductsPreclinical Products/Combination Treatment ModalitiesCerecor Inc. - Drug ProfilesCERC-Product DescriptionMechanism of ActionR&D Progressmemantine hydrochlorideProduct DescriptionMechanism of ActionR&D Progress2-MPPAProduct DescriptionMechanism of ActionR&D ProgressSmall Molecules to Inhibit COMT for Cognitive DisordersProduct DescriptionMechanism of ActionR&D ProgressCerecor Inc. - Pipeline AnalysisCerecor Inc. - Pipeline Products by TargetCerecor Inc. - Pipeline Products by Route of AdministrationCerecor Inc. - Pipeline Products by Molecule TypeCerecor Inc. - Pipeline Products by Mechanism of ActionCerecor Inc. - Recent Pipeline UpdatesCerecor Inc. - Dormant ProjectsCerecor Inc. - Discontinued Pipeline ProductsDiscontinued Pipeline Product ProfilesCERC-Cerecor Inc. - Locations And SubsidiariesHead OfficeAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer 


LIST OF TABLESCerecor Inc., Key InformationCerecor Inc., Key FactsCerecor Inc. - Pipeline by Indication, 2014Cerecor Inc. - Pipeline by Stage of Development, 2014Cerecor Inc. - Monotherapy Products in Pipeline, 2014Cerecor Inc. - Phase II, 2014Cerecor Inc. - Preclinical, 2014Cerecor Inc. - Pipeline by Target, 2014Cerecor Inc. - Pipeline by Route of Administration, 2014Cerecor Inc. - Pipeline by Molecule Type, 2014Cerecor Inc. - Pipeline Products by Mechanism of Action, 2014Cerecor Inc. - Recent Pipeline Updates, 2014Cerecor Inc. - Dormant Developmental Projects,2014Cerecor Inc. - Discontinued Pipeline Products, 2014 


LIST OF FIGURESCerecor Inc. - Pipeline by Top 10 Indication, 2014Cerecor Inc. - Pipeline by Stage of Development, 2014Cerecor Inc. - Monotherapy Products in Pipeline, 2014Cerecor Inc. - Pipeline by Top 10 Target, 2014Cerecor Inc. - Pipeline by Top 10 Route of Administration, 2014Cerecor Inc. - Pipeline by Top 10 Molecule Type, 2014Cerecor Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
        
        
Skip to top




MORE PUBLICATIONS


Beech Tree Labs, Inc. - Product Pipeline Review - 2014
US$ 1,500.00
May, 2014 · 33 pages


ChemoCentryx, Inc. - Product Pipeline Review - 2016
US$ 1,500.00
Sep, 2016 · 56 pages


Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2015
US$ 1,500.00
Nov, 2015 · 29 pages








Ask Your Question
Cerecor Inc. - Product Pipeline Review - 2014







Company name*:



Contact person*:



Phone/fax*:



Email*:




 Request invoice


Your enquiry:




				Please click on a Check Box below to confirm you are not a robot:
					


























Market Reports


All Categories  Biotechnology Biomarkers Biomaterials Biosimilars Stem Cell  Diagnostics & Diseases In Vitro Diagnostics Incontinence Cancer Cardiovascular Diabetes Hepatitis  Healthcare Healthcare Services Company Reports Ear Care Eye Care Hospital Medicated Skin Care Therapy Wound Care  Medical Devices Anesthesia & Respiratory Cardiovascular Devices Dental Devices Diabetes Care Diagnostic Equipment Endoscopy Ear, Nose & Throat (ENT) Devices Healthcare Equipment/Supplies Company Reports Neurology Orthopedic Devices Ophthalmic Surgical Equipment Wound Closure Other Medical Devices  Medical Products Pharmaceuticals Clinical Trials Drug Stores Drugs Pharmaceuticals Company Reports Vaccines  Veterinary 












Sales and support:
                    +44 20 8123 2220
            +1 732 587 5005
info@marketpublishers.com
  © 2006-2016 MarketPublishers.com


About Us
Our Clients
Our Publishers
Customer FAQ


Market Reports
New Publications
Reports by Regions
Press-Releases


Terms & Conditions
Privacy Policy
Return Policy
Affiliate Program


Join as Publisher

Follow Us:


























Cerecor Inc - Supplier | Peru | Import Genius
































 












Plans




Limited




Plus




Premium








            LimitedMonitor Your Competitors



Data

Access data on U.S. ocean freight imports from the last 3 months for all companies
You'll have access to data from the previous 6-months from the date of your search. We use a rolling date range, so you can always look back 6 months from the current date.




            LimitedMonitor Your Competitors



Data

Access data on U.S. ocean freight imports from the last 3 months for all companies
Access data on U.S. ocean freight imports from the last 3 months for all companies
You'll have access to data from the previous 3-months from the date of your search. We use a rolling date range, so you can always look back 3-months from the current date.




            PlusSmall & Medium Business



Data

Access data on U.S. ocean freight imports from the last 12 months for all companies
You'll have access to data from the previous 12-months from the date of your search. We use a rolling date range, so you can always look back 12-months from the current date.
U.S. ocean freight exports from January 1, 2014 to present for all companies




            Premium            Empire Builder



Data

Access data on U.S. ocean freight imports from November 2006 to the present for all companies
You'll have access to our entire database of shipping manifests of U.S. Ocean freight imports going back to November 2006.
U.S. ocean freight exports from January 1, 2014 to present for all companies





            LimitedMonitor Your Competitors



Usage

Track the shipping activities of your 3 chosen companies
Our Limited Plan lets you monitor the shipping activities of any three companies across all our databases. Be the first to know when your target company clears a shipment through customs in one of the countries we track.
3 Contact Info Requests Per Month
Our team of account managers and research assistants will help you find contact information for up to 3 companies in our database each month.
Download (CSV and XLS) 5k Records Per Month
If you're planning to do more in-depth research on the companies in our database, you should upgrade to the Plus or Premium plans, which allow more downloads.
Email Alerts for up to 3 Searches
If you need to track more than 3 companies, product segments, or trade lanes, you should upgrade to the Plus or Premium plan, which allow more email alerts.




            LimitedMonitor Your Competitors



Usage

10 Company Searches Per Day
10 searches per day may be enough if you are just monitoring a few competitors or researching suppliers in a single industry. If you're looking to connect with sales leads or do more in-depth research, you should upgrade to the Plus or Premium plan which allows more searches.
3 Contact Info Requests Per Month
Our team of account managers and research assistants will help you find contact information for up to 3 companies in our database each month.
Download (CSV and XLS) 1k Records Per Month
If you're planning to do more in-depth research on the companies in our database, you should upgrade to the Plus or Premium plan, which allow more downloads.
Email Alerts for up to 3 Company Searches
If you need to track more than 3 companies, product segments, or trade lanes, you should upgrade to the Plus or Premium plan, which allow more email alerts.




            Plus            Small & Medium Business



Usage

25 Searches Per Day
25 searches per day may be enough if you are just monitoring a few competitors or researching suppliers in a single industry. If you're looking to connect with sales leads or do more in-depth research, you should upgrade to the Premium plan which allows more searches.
25 Contact Info Requests Per Month
Our team of account managers and research assistants will help you find contact information for up to 25 companies in our database each month.
Download (CSV and XLS) 10k Records Per Month
If you're planning to do more in-depth research on the companies in our database, you should upgrade to the Premium plan, which allow more downloads.
Email Alerts for up to 5 Searches
If you need to track more than 5 companies, product segments, or trade lanes, you should upgrade to the Premium plan, which allow more email alerts.




            Premium            Empire Builder



Usage

50 Searches Per Day
 
50 Contact Info Requests Per Month
Our team of account managers and research assistants will help you find contact information for up to 50 companies in our database each month
Download (CSV and XLS) 25k Records Per Month
If you're planning to do more in-depth research on the companies in our database, contact the Sales Department to purchase more credits and export additional shipping records.
Email Alerts for up to 10 Searches





             Plus             Small & Medium Business



Features

Visual Mapping
Our Visual Mapping technology provides an instant snapshot of any company's trade connections. Navigate the global web of trading partners with the click of a mouse and visualize the relationships between companies many degrees apart.







            Premium            Empire Builder



Features

Visual Mapping
Our Visual Mapping technology provides an instant snapshot of any company's trade connections. Navigate the global web of trading partners with the click of a mouse and visualize the relationships between companies many degrees apart.







            Limited            Monitor Your Competitors



Support

Our Customer Service Agents are available when you need them. Call in to receive helpful tips and training.
Call or e-mail our Customer Service Agents. They will get back to as soon as possible to assist you with your data needs.




            Plus            Small & Medium Business



Support

Our Customer Service Agents are available when you need them. Call in to receive helpful tips and training.
Call or e-mail our Customer Service Agents. They will get back to as soon as possible to assist you with your data needs.




            Premium            Empire Builder



Support

Our Customer Service Agents are available when you need them. Call in to receive helpful tips and training.
Call or e-mail our Customer Service Agents. They will get back to as soon as possible to assist you with your data needs.
Dedicated Research Assistant
An experienced trade data specialist will serve as your dedicated account manager to locate hard-to-reach data, perform searches and compile reports on your behalf.




            Limited            Monitor Your Competitors



Data

Access data on U.S. ocean freight imports from the last 3 months for all companies
You'll have access to data from the previous 6-months from the date of your search. We use a rolling date range, so you can always look back 6 months from the current date.







X












                   Home                





                        How It Works                    



                            U.S. Data                        

                            Additional Countries                        

                            Our Datasets                        

                            Our Clients                        

                            IG Reviews                        

                            Videos                        

                            Pictures                        

                            Presentation                        



                   Plans & Pricing                

                    Search                

                  Contact Us                
Live Chat				

                    Free Demo                

                    Sign In                

                    Join Now                











English
中文
French










English



中文



French










			                                                Service: 855-573-9976 
                        Sales: +1-855-573-9976

 Live Chat

Choose Language
 English
 中文
 French




 



Hi, may I help you with something?

An ImportGenius.com sales agent is available to answer your question.


							Chat Live Now						

						No, thanks.					







Sign Up






Home
How It Works
Plans & Pricing
Search
Contact Us


Live Chat

2
  



 





Cerecor Inc

Cerecor Inc is an overseas supplier in United States that exports products to Icon Clinical Research Peru Sa via New Yo.        





 Call +1 (480) 744 2559




Import Genius






                                Our bill of lading data reveals the trading activities of Cerecor Inc and millions of other manufacturers.                            


Learn More
Join Now




Request a Demo





Would you like to schedule a free demo?
We'd love to show you international trade data relevant to your own business.










Name




Email





Phone






Schedule A Free Demo


















Play muted


International Trade Starts With Our Data









Other companies in our database


 AMPLIVOX LTD                            

 SOLARI INTERNACIONAL SRLTDA                            

 DEE INDIA IMPORT AND EXPORT SOCIEDAD ANONIMA CERRADA - DEE INDIA                            

 OSTEOSYS CO LTD                            

 LAMEX FOODS INC8500 NORMANDALE LAKE BLVDSUITE 115                            
















View Sample Shipment Records
Shipment Alert Subscription
Contact This Company



Sign Up

 





Sample shipment record for Cerecor Inc
Cerecor Inc is an overseas supplier in United States that exports products to Icon Clinical Research Peru Sa via New Yo.


            Bill of Lading        





Manufacturer / Shipper
Consignee



Cerecor Inc


Icon Clinical Research Peru Sa




Acquisition
Embarkation



Estados Unidos


New Yo



Product Description





                                        GRABADORA, PHILIPS, LFH0865                                    

                                        GRABADORA, PHILIPS, LFH0865                                    





Other Information Available




HS Code Description, FOB (USD), Freight (USD), Insurance (USD), Package Type, Net Weight








Arrival Date2012-07-09HS Code8519899000CustomsAEREA DEL CALLAOQuantity / Unit1.00/UNIDAD 





Subscribe to access the complete shipping history for Cerecor Inc Join Now








How will your business use our trade data?
If you're involved in international trade, our database of shipping manifests will help you find opportunities to grow your business.

Find Trading Partners You Can Trust
Monitor Competitors' Shipping Activities
Connect With Sales Prospects














                            "Very informative and great site and so quick. Pretty slick."
                        







Betty Fatzie

                                                                    President,                                 
                                                                    Lab Products, Inc.                                
                            






                            "The service was great, with a reasonable price and great results. We have now started using another supplier from China. We just ordered our first container from the new supplier and with the savings it more than paid for the ImportGenius.com service on the first container load."
                        







Cleve Kurz

                                
                                                                    Gifford Monument Works                                
                            






                            "Import Genius is not merely an investment for our organization, it’s a vital instrument to effectively manage our time. It has afforded us the ability to quickly segment, target and position ourselves in front of prospective clients. Thank you, Import Genius!"
                        







David Bryant

                                                                    Director of Business Development,                                 
                                                                    John S. James Co.                                
                            






                            "Import Genius data is fantastic for evaluating component manufacturers in China."
                        







Sanjay Dastoor

                                
                                                                    BoostedBoards.com                                
                            






                            "We have confidence that we're working with the best manufacturers in part because Import Genius showed us that they already supply some of the world's top brands"
                        







Yaniv Masjedi

                                                                    Vice President,                                 
                                                                    Nextiva.com                                
                            






                            "Import Genius is a highly informative tool for monitoring public companies' operating activities. It is an invaluable part of our research."
                        







Eric DeLamarter

                                                                    Managing Partner,                                 
                                                                    Half Moon Capital                                
                            






                            "We find new clients for our customs brokerage in the ImportGenius database almost every day"
                        







Jayson Gispan

                                                                    Customs Brokerage Operations Manager,                                 
                                                                    Flexport.com                                
                            






                            "ImportGenius is a great research tool. We use it to evaluate manufacturers to make sure we are working with only the highest quality, most reliable suppliers"
                        







Chris Friedland

                                                                    Founder / CEO,                                 
                                                                    Build.com                                
                            






                            "ImportGenius gave us visibility into the actual shipping histories of the manufacturers we were evaluating and helped us feel comfortable we were working with the best suppliers in China."
                        







Morena Simitic

                                                                    COO,                                 
                                                                    BellaBeat.com                                
                            
























Shipment Alert Subscription



                        Receive free shipment alerts by email whenever Cerecor Inc clears a shipment through customs.                        

Processing, please wait ...







Submit












Contact Cerecor Inc










 



Name



Business



Email



Phone




Submit




Processing, please wait ...

 

 




Features



Save and Share Reports
Easily get your searches out of Import Genius and into your team’s hands for further analysis. Export your findings to XLS or CSV, or send reports via email. It’s the simple things that make our trade data even more valuable to you.



See the Supply Chain
Visual Mapping shows you exactly how your target companies and their trading partners connect. Search by shipper and see everyone they’ve shipped to. Or search by consignee and see all their suppliers. Zoom in on any company to see their own trading network. Dive deep into international trade and discover the links in anyone’s supply chain.



Get Real-time Shipment Alerts
Stay on top of your competitors, suppliers, and customers with real-time alerts. Just set up a search and get an email whenever a new shipment matches your terms. Import Genius lets you know the moment they bring in a rival product or start shipping to a new partner.









Cerecor Inc
You've viewed 20 profile pages on Import Genius, which is the most we allow for free. Sign up for ImportGenius to get more details on over 3 million importers and exporters. It only takes seconds.






Sign Up for Import Genius! 








Plans




Limited
Monitor Your Competitors




Recommended Plan
Plus
Small & Medium Business




Premium
Empire Builder






Price





$
99
594
/month
for 6 months



                        Sign Up                    






$
199
1,194
/month
for 6 months



                        Sign Up                    






$
399
2,394
/month
for 6 months



                        Sign Up                    







Data




Access data on U.S. ocean freight imports from the last 3 months for all companies
View Details




Access data on U.S. ocean freight imports from the last 12 months for all companies
U.S. ocean freight exports from January 1, 2014 to present for all companies
View Details




Access data on U.S. ocean freight imports from November 2006 to the present for all companies
U.S. ocean freight exports from January 1, 2014 to present for all companies
View Details






Usage





Track the shipping activities of your 3 chosen companies
3 Contact Info Requests Per Month
Download (CSV and XLS) 5k Records Per Month
Email Alerts for up to 3 Searches

View Details





25 Searches Per Day
25 Contact Info Requests Per Month
Download (CSV and XLS) 10k Records Per Month
Email Alerts for up to 5 Searches

View Details





50 Searches Per Day
50 Contact Info Requests Per Month
Download (CSV and XLS) 25k Records Per Month
Email Alerts for up to 10 Searches

View Details






Features


 


Visual Mapping
View Details




Visual Mapping
View Details






Support




Our Customer Service Agents are available when you need them. Call in to receive helpful tips and training.
View Details




Our Customer Service Agents are available when you need them. Call in to receive helpful tips and training.
View Details





Our Customer Service Agents are available when you need them. Call in to receive helpful tips and training.
Dedicated Research Assistant

View Details






  






View All U.S. Imports
Instantly search 38,562,916 ocean freight records to monitor U.S. importers, research suppliers, generate sales leads and more.


As Featured In






















What is Import Genius





Who Uses Import Genius





Available Data Fields





Schedule Live Demo







What is Import Genius


												Import Genius reveals the trading activities of importers and exporters around the world.								

												We give you hard data about your overseas suppliers and domestic competitors. Using shipping databases from Customs agencies in the United States, Latin America, and India, Import Genius can help you find reliable new trading partners, monitor your competitors’ shipments, and keep an eye on your current suppliers and customers.								

												Our team of seasoned import-export veterans, cutting-edge software developers, and customer service professionals has worked for years to build the world's most powerful and accessible database of international trade intelligence.								



												We do this for a diverse client base that requires keen insight into international trade.								

												Our customers include some of the world's top importers, exporters, freight forwarders, logistics companies, manufacturers, investment banks, financial analysts, intellectual property attorneys, and more. They use our tools to:								

Research the trade activity of importers and suppliers
Identify and vet new sources for any kind of product
Monitor the competition and their trade connections
Generate sales leads for transportation and logistics companies
Track the activity of publicly-traded companies
Investigate and enforce intellectual property infringement
Ensure exclusive agent compliance




Who Uses Import Genius

Sourcing Professionals...

			Use our service to view shipping histories for suppliers.		

			We provide access to detailed customs records, letting you verify suppliers' true shipping volumes and U.S. customer lists. You can also look up your competing import firms to find where they buy their goods.		
+ Learn More
Competitive Intelligence Analysts...

			Use our service to learn where rivals source products.		

			We give clear insights into the importing volumes, new product releases, and broader competitive dynamics of your industry.		
+ Learn More


Sales & Marketing Teams...

			Use our service to generate sales prospects.		

			We give you the tools to target importers based on product type, location, shipping volumes, and more.		
+ Learn More
Financial Analysts...

			Use our service to monitor public companies' imports.		

			We offer rare data on the success or failure of new product launches, shipping trends and other operating data for companies in any industry.		
+ Learn More



Available Data Fields

Import Genius Data Fields

												By collecting the ocean freight bill of lading for all U.S. imports in our database, Import Genius provides unprecedented access to near real-time information on virtually every industry and company importing goods into the country.								

												For each shipment entering the U.S. by ocean, we provide access to the following information.								
Additional Fields Available for Some Shipments:

Phone Number
Fax Number
Email
Contact Person



List of Data Fields



ConsigneeThe company importing the shipment into the U.S.Consignee AddressThe address of the company importing the shipment into the U.S.ShipperThe overseas company exporting the shipment to the U.S.Shipper AddressThe address of the overseas company exporting the shipment to the U.S.Product DescriptionThe exporter's description of the shipment as it appears on the bill of lading or shipping manifestGross WeightThe gross weight of the shipment, excluding the weight of the actual container. This can appear in either pounds or kilograms at the discretion of the exporterNumber Of UnitsThe quantity of boxes customs would find if they were to open the shipment for inspection.VolumeThe volume of the shipment, generally defined in cubic meters or container base measurements (CBM)Arrival DateThe date the shipment arrives within the customs territory of the U.S.Foreign PortThe last port the shipment passes through before arriving in the U.S.Country Of OriginThe country of the last foreign port the shipment passes through before arriving in the U.S.U.S. PortThe U.S. port where the shipment enters the customs territory of the U.S.Carrier CodeThe four digit Standard Carrier Alpha Code of the ocean carrier or freight forwarder managing the transit of the shipmentVoyage NumberA unique code assigned to that particular sailing of the ship between two portsVessel NameThe name of the ship transporting the shipmentShip Registered InThe country where the ship is officially registeredBill Of Lading NumberThe unique number assigned to this particular shipment by the ocean carrier or freight forwarderContainer NumberThe unique number assigned to the ocean shipping container carrying the shipment in questionMarks & NumbersAny text or numbers appearing on the cartons 






Ready for a live demo?
Fill out this form and we'll contact you right away to set up a live demo of Import Genius.


Schedule Live Demo



Processing, please wait ...





Name

Tell us your Full Name


Email

Enter a valid email address


Phone

Enter valid phone number


Preferred Date

Let us know your preferred date


Preferred Time (In Your Country)

01:00 am
01:30 am
02:00 am
02:30 am
03:00 am
03:30 am
04:00 am
04:30 am
05:00 am
05:30 am
06:00 am
06:30 am
07:00 am
07:30 am
08:00 am
08:30 am
09:00 am
09:30 am
10:00 am
10:30 am
11:00 am
11:30 am
12:00 am
12:30 am
01:00 pm
01:30 pm
02:00 pm
02:30 pm
03:00 pm
03:30 pm
04:00 pm
04:30 pm
05:00 pm
05:30 pm
06:00 pm
06:30 pm
07:00 pm
07:30 pm
08:00 pm
08:30 pm
09:00 pm
09:30 pm
10:00 pm
10:30 pm
11:00 pm
11:30 pm
12:00 pm

Let us know your preferred time


Country

Required


Timezone

Required


What data are you interested in?

Let us know what you are most interested to learn



Submit



 















Import Genius

How It Works
Plans & Pricing
Our Trade Data Blog
Search
Latin Trade Data

Import Genius Reviews & Press Coverage
Who Uses Import Genius
Contact Us



Latest Posts




                                    Trump Properties Have…                                




                                    Solar panels: imports…                                




                                    Limited Plan Now Available                                




                                    Chilean salmon exports…                                




                                    India, US palm oil imports…                                




Company Profiles



                                    Emerson Network Power Srl                                



                                    Rts Automation S.a.c.                                



                                    Rimachi Jimenez Americo                                



                                    Precision Material Handling Equipment                                



                                    Carlessi Sac                                











                     
                                            38,562,916  Records in our database and counting





Customer Support Team: 

                    Tel:  855-573-9976
                    International: +1 480-745-3396
                    Fax: +1 602-428-9400
info@importgenius.com

                    8901 E Pima Center Pkwy, 
		    Suite 105 
                    Scottsdale, AZ 85258


Shanghai, China:

                    Tel: +86-21-63806036


                    Mobile No.: +86-13671737628
                    Fax Number: +86-21-63806036


Shenzhen, China
                    
                            Tel: +86-755-89517585
                            Mob: +86-13925258002
                            Fax: +86-755-89517585                



Have questions? We'll reply quickly!





									         		Type your info below								         		











Message



Submit

Processing, please wait ...

 

 

                Trainings, Demos, and General Contact All Available            
Or Call Us:
Service:

                    +1-855-573-9976                
Sales:

                    +1-855-573-9976                
Back to top

 





All Rights Reserved. Copyright © 2017. Trade Data Services, Inc. 0.1675
 






 

 




We're Offline
Please leave us a message



To chat with a representative of Import Genius, your browser needs to be Internet Explorer 9 or higher. Please fill out the form below and a representative will contact you as soon as possible.



Name



Email



Phone



Message



Send




X















